ライフサイエンスコーパス: muscarinic agonist

1 y multiple calcium responses to carbachol, a muscarinic agonist.

2 24Z is functionally an m1-selective muscarinic agonist.

3 d 63% by 10 microM oxotremorine M (Oxo-M), a muscarinic agonist.

4 nd is classified as either a full or partial muscarinic agonist.

5 h is known to be an M(1)- and M(4)-selective muscarinic agonist.

6 rol M-current over-recovery after washout of muscarinic agonist.

7 A-090, an NMDA antagonist; and WAY-132983, a muscarinic agonist.

8 tion--when worms are exposed to arecoline, a muscarinic agonist.

9 2+) influx and release elicited by different muscarinic agonists.

10 underlie the cognition-enhancing effects of muscarinic agonists.

11 upon either ACh release or its modulation by muscarinic agonists.

12 ator circuit within CA1 that is activated by muscarinic agonists.

13 ut can fire spontaneously when stimulated by muscarinic agonists.

14 minal kinase activation by neuropeptides and muscarinic agonists.

15 thyl-D-aspartate (NMDA)-receptor currents by muscarinic agonists.

16 larizing current stimulus in the presence of muscarinic agonists.

17 int for the development of desired selective muscarinic agonists.

18 one, and asthmatics exhibit increased AHR to muscarinic agonists.

19 eral responses associated with non-selective muscarinic agonists.

20 nt mutant receptors with full versus inverse muscarinic agonists.

21 in magnitude and somewhat less than that by muscarinic agonists.

22 -cells, and these processes are amplified by muscarinic agonists.

23 ation by acetylcholine, carbachol, and other muscarinic agonists.

24 1,4-dioxane scaffold of the potent M(2)/M(3) muscarinic agonist 1 with bulkier groups.

25 iazoles to provide a new series of potent m1 muscarinic agonists 17 and 18.

26 The acetyl group of the muscarinic agonist aceclidine 4 was replaced by various

27 The muscarinic agonist acetylcholine (10 micrograms/kg IV) i

28 overcome by increasing concentrations of the muscarinic agonist acetylcholine but was progressively l

29 The muscarinic agonist ACh inhibited the Ca(2+) current stim

30 The data suggest that muscarinic agonists act as functional dopamine antagonis

31 timulation of these mAChRs with carbachol, a muscarinic agonist, activated extracellular-regulated ki

32 Nicotine, but not muscarinic agonists, activates postsynaptic receptors an

33 tetrahydropyrimidine derivatives exhibiting muscarinic agonist activity in rat brain.

34 and tested for receptor binding affinity and muscarinic agonist activity.

35 Systemic administration of 3 M1-selective muscarinic agonists, AF102B, AF150S and AF267B, decrease

36 the therapeutic efficacy of the selective M1 muscarinic agonist AF267B in the 3xTg-AD model of Alzhei

37 Intraseptal muscarinic agonists also alleviate the amnesic syndrome

38 Remarkably, muscarinic agonists also cause long-term (>30 min) suppr

39 Specific nicotinic and muscarinic agonists also elevated [Ca2+]i in a dose-depe

40 However, muscarinic agonists also elicit a long-term (2 hr) suppr

41 Muscarinic agonists also induce and atropine potently in

42 bradykinin, but reduced I(M) suppression by muscarinic agonist and angiotensin II.

43 Interestingly, incubation with classical muscarinic agonists and antagonists or allosteric ligand

44 ng kinetics and pharmacological responses to muscarinic agonists and GTPgammaS.

45 basis for the opposing biological effects of muscarinic agonists and inverse agonists.

46 neuroblastoma and sympathetic neurons, both muscarinic agonists and nitric oxide (NO) rapidly elevat

47 iments on neuroblastoma cells show that both muscarinic agonists and NO rapidly elevate cGMP.

48 Oxotremorine (a muscarinic agonist) and (-)butylthio[2.2.2] (a mixed mus

49 2+) and 2.5 microm oxotremorine M (oxo-M), a muscarinic agonist, and fully blocked by zero Ca(2+), 10

50 receptors yielded large [Ca(2+)](i) rises by muscarinic agonist, and transfection of wild-type IRBIT

51 strongly depolarized by bath application of muscarinic agonists, and uniformly lacked a similar musc

52 ic agonist) and (-)butylthio[2.2.2] (a mixed muscarinic agonist/antagonist) dose-dependently inhibite

53 ing of the specific mechanisms through which muscarinic agonists are likely to modulate neuronal exci

54 injections of cholinomimetic drugs, either a muscarinic agonist (arecoline, pilocarpine or oxotremori

55 he development of receptor subtype-selective muscarinic agonists as novel analgesic drugs.

56 systemic pretreatment with the pro-motility muscarinic agonist bethanechol, but were abolished by sy

57 lacking RGS4 in pancreatic beta-cells with a muscarinic agonist (bethanechol) led to significantly in

58 gastric motility in rats pretreated with the muscarinic agonist, bethanecol (P < 0.05).

59 Disulfide cross-linking studies showed that muscarinic agonists, but not antagonists, promoted the f

60 f muscarinic receptors as it was mimicked by muscarinic agonists, but not by nicotine, and was blocke

61 In the presence of muscarinic agonists, Ca2+i responses consisted of an ini

62 vitro evidence that a brief application of a muscarinic agonist can transiently synchronize islets.

63 native or recombinant channels inhibited by muscarinic agonists can be activated by PIP(2).

64 reated with ethanol, and stimulated with the muscarinic agonist carbachol (1 muM).

65 -40 mV), and were inhibited by bath-applied muscarinic agonist carbachol (10 microm).

66 The mixed muscarinic agonist carbachol (CAR) hyperpolarized all ty

67 Acinar cell responses to the muscarinic agonist carbachol (CCh) and the bile acid tau

68 The effects of the cholinergic muscarinic agonist carbachol (CCh) on the basal L-type c

69 The muscarinic agonist carbachol also prevented beta-AR-stim

70 a contractile phenotype that responds to the muscarinic agonist carbachol and is not immediately reve

71 sis when the cells are preincubated with the muscarinic agonist carbachol for > or = 5 min and forsko

72 -methyl-D-aspartate receptor currents by the muscarinic agonist carbachol in hippocampal pyramidal ce

73 The muscarinic agonist carbachol increased IK+Ach activity i

74 dye fluo-4 AM were captured; exposure to the muscarinic agonist carbachol increased the fluorescence

75 The muscarinic agonist carbachol induced pronounced transien

76 lastoma cells, activation of ADAM10 with the muscarinic agonist carbachol promotes PrP(C) shedding an

77 ary cells expressing m3 mAChRs, doses of the muscarinic agonist carbachol ranging from 100 nM to 1 mM

78 Application of the muscarinic agonist carbachol reduced peak Na+ current an

79 In this system, the muscarinic agonist carbachol stimulated steady-state PLC

80 A half-maximal effect of the muscarinic agonist carbachol was observed at approximate

81 lls, in acini stimulated to secrete with the muscarinic agonist carbachol, and in acini shrunken by h

82 P by approximately 90% in the absence of the muscarinic agonist carbachol, indicating that these tyrp

83 to the negative chronotropic effects of the muscarinic agonist carbachol.

84 isolated smooth muscle cells induced by the muscarinic agonist carbachol.

85 ccurred in eggs in low pH in response to the muscarinic agonist carbachol.

86 phorylation and contractile responses to the muscarinic agonist carbachol.

87 imulation of beta cells with glucose and the muscarinic agonist carbachol.

88 al rat ventricular myocytes treated with the muscarinic agonist carbachol.

89 tion upon pharmacological treatment with the muscarinic agonist carbachol.

90 ractility in the presence and absence of the muscarinic agonist carbachol.

91 transients were generated on exposure to the muscarinic agonist carbachol.

92 esponse curves have been constructed for the muscarinic agonists carbachol, acetylcholine, and piloca

93 In BHK cells expressing M1 receptors, a muscarinic agonist (carbachol) causes a 40% decrease of

94 We have shown previously that the muscarinic agonist, carbachol (CCh), transactivates the

95 cross-linking experiments revealed that the muscarinic agonist, carbachol, promoted the formation of

96 wing treatment with PMA or the acetylcholine muscarinic agonist, carbachol.

97 her in the absence or in the presence of the muscarinic agonist, carbachol.

98 th in the absence and in the presence of the muscarinic agonist, carbachol.

99 s abolished) the attenuation of ICa-L by the muscarinic agonist carbamylcholine (CCh).

100 ICa-L had been previously attenuated by the muscarinic agonist carbamylcholine (CCh, 1 mumol/L), SIN

101 rasympathetic inhibition of beat rate by the muscarinic agonist, carbamylcholine, by 5-fold and decre

102 Muscarinic agonists cause a rapid increase in presynapti

103 Activation of this pathway with muscarinic agonists caused UNC-13 to accumulate in punct

104 that treatment of chick embryos in ovo with muscarinic agonist causes decreases in mRNA levels encod

105 In contrast, two novel muscarinic agonists chemically derived from epibatidine,

106 The M1 muscarinic agonist CI-1017 was administered intravenousl

107 by reduced insulin secretion in response to muscarinic agonists, combined with increased peripheral

108 Selective muscarinic agonists could be useful in the treatment of

109 studies were conducted to determine whether muscarinic agonists could change outflow facility in per

110 Muscarinic agonists decreased AC activity, LVEF, and hea

111 duced (or stabilized) by full versus inverse muscarinic agonists differ from each other at the molecu

112 Centrally active muscarinic agonists display pronounced analgesic effects

113 rons in rat brain slices, we have found that muscarinic agonists do not excite septohippocampal choli

114 Muscarinic agonists do not induce dauer recovery of eith

115 ground conductances strongly attenuated most muscarinic agonist effects, with the notable exception t

116 unds with high muscarinic affinity and/or m1 muscarinic agonist efficacy were also obtained when the

117 Muscarinic agonists elevate cGMP by triggering Ca2+ mobi

118 Muscarinic agonists evoked reflexes that were associated

119 edly without decrement, whereas responses to muscarinic agonists exhibit a profound and prolonged des

120 However, infusion of either nicotinic or muscarinic agonists failed to improve choice accuracy.

121 rt to design and synthesize highly selective muscarinic agonists for different muscarinic receptor su

122 We also demonstrated that full and inverse muscarinic agonists had distinct effects on the efficien

123 , two other (nor)tropanes, and the classical muscarinic agonists had higher affinity versus agonist b

124 Many muscarinic agonists have been developed, yet most exhibi

125 Previously developed muscarinic agonists have provided clinical data in suppo

126 current potassium channel activity evoked by muscarinic agonists in sympathetic ganglion neurons is c

127 ellular mechanisms underlying the effects of muscarinic agonists in the MSDB involve an excitation of

128 X-sensitive IK(Ca) could be activated by the muscarinic agonists in the presence or absence of extern

129 produced by CI-1017, an M(1)/M(4) selective muscarinic agonist, in the mesolimbic region and striatu

130 Muscarinic agonists increase outflow facility in human e

131 Muscarinic agonists increased the input resistance of ne

132 s transiently expressing the m2 mAChR with a muscarinic agonist induced an approximately 4- or 8-fold

133 s STIM1 and STIM2 decreased the magnitude of muscarinic agonist induced oscillatory calcium release a

134 Although muscarinic agonists induced robust activation of MAPK in

135 treatment of caged bees with pilocarpine, a muscarinic agonist, induced an increase in the volume of

136 AA, and inhibiting iPLA(2)beta prevents the muscarinic agonist-induced accelerated Kv2.1 inactivatio

137 Strikingly, muscarinic agonist-induced antinociception was totally a

138 t M(5) receptors play a role in facilitating muscarinic agonist-induced dopamine release in the stria

139 Finally, muscarinic agonist-induced InsP3R ubiquitination was see

140 Previous work has suggested that muscarinic agonist-induced jaw movements in rats were re

141 DHEAS reduced muscarinic agonist-induced Kv7-current suppression of Kv

142 Finally, muscarinic agonist-induced smooth muscle contraction als

143 Carbachol, a muscarinic agonist, induces prolonged activation of ERKI

144 iewed have promising clinical data, with the muscarinic agonist KarXT most advanced.

145 sented including with activity data of three muscarinic agonists measured in rabbit myocardium.

146 xamined the roles of M(1) and M(3) mAChRs in muscarinic agonist-mediated stimulation of salivary secr

147 HEK293) cells with low concentrations of the muscarinic agonist methacholine results in the activatio

148 Airway resistance responses (Raw) to the muscarinic agonist methacholine were measured by using t

149 Muscarinic agonists might be useful in the treatment of

150 Here, we characterize the clinical-stage muscarinic agonist ML-007 in preclinical models and expl

151 In neurons, muscarinic agonists mobilize an AKAP79-anchored pool of

152 Muscarinic agonists modulate N- and L-type Ca(2+) channe

153 m exposures of cultured KCs to PV IgG or the muscarinic agonist muscarine both induced changes in the

154 The parasympathetic responses to a muscarinic agonist, namely I(KACh) activation in SAN cel

155 The muscarinic agonist of chloride secretion, carbachol (CCh

156 In vitro stimulation with a muscarinic agonist of submandibular gland cells isolated

157 ibility that there may be a direct effect of muscarinic agonists on outflow facility.

158 effects of bradykinin and oxotremorine-M (a muscarinic agonist) on membrane PIP(2) in sympathetic ne

159 ved whether the channels were activated by a muscarinic agonist or by OAG.

160 administered without prior administration of muscarinic agonist or cholinesterase inhibitor) produced

161 cotine but contracted when stimulated with a muscarinic agonist or electric field stimulation.

162 se but potentiated the stimulation by either muscarinic agonists or 2-methyl-thio-ADP.

163 either in the absence or in the presence of muscarinic agonists or antagonists.

164 timulating mouse-eye pupil constriction than muscarinic agonists oxotremorin-M (Oxo-M) or carbachol (

165 muscarinic activation with the nonselective muscarinic agonist oxotremorine inhibits rebound activit

166 om wild-type mice, the non-subtype-selective muscarinic agonist oxotremorine led to concentration-dep

167 The muscarinic agonist oxotremorine methiodide (oxo-M) stimu

168 isolate the slow pathway, we found that the muscarinic agonist oxotremorine methiodide not only inhi

169 The muscarinic agonist oxotremorine methiodide produced a do

170 The muscarinic agonist oxotremorine restores the plateau pot

171 The nonselective muscarinic agonist oxotremorine showed reduced analgesic

172 Using the muscarinic agonist oxotremorine, we revealed a unique co

173 bellar slices, we have demonstrated that the muscarinic agonist oxotremorine-m (oxo-m) blocks the ind

174 c KCNQ2/KCNQ3 currents were modulated by the muscarinic agonist oxotremorine-M (oxo-M) in a manner ha

175 n, following treatment with the nonselective muscarinic agonist oxotremorine-M, M2, and M4 receptors

176 iology studies, 27b blocked the nonselective muscarinic agonist oxotremorine-M-induced increases in n

177 itivity upon challenge with the nonselective muscarinic agonist oxotremorine.

178 The standard muscarinic agonists oxotremorine and pilocarpine were bo

179 ine were 60-75% of the magnitude of the full muscarinic agonists oxotremorine-M and cis-dioxolane.

180 The nonsubtype-selective muscarinic agonist, oxotremorine (0.1-10 microm), inhibi

181 ctivity in the thoracic ganglia by using the muscarinic agonist pilocarpine and enforced the stepping

182 The M(1) muscarinic agonist pilocarpine blocked phosphorylation o

183 in electroencephalograms, SE induced by the muscarinic agonist pilocarpine in mice is preceded by a

184 Systemic administration of the nonselective muscarinic agonist pilocarpine induces pronounced striat

185 Application of the muscarinic agonist pilocarpine mimicked the effect of IP

186 n applied at a low dose (1 mg/kg, s.c.), the muscarinic agonist pilocarpine showed significantly redu

187 The ability of the partial muscarinic agonist pilocarpine to increase in vivo phosp

188 receptor function tested 24 h later with the muscarinic agonist pilocarpine.

189 s produced by systemic administration of the muscarinic agonist pilocarpine.

190 ring walking or during rhythms evoked by the muscarinic agonist pilocarpine.

191 nce to seizures induced by the non-selective muscarinic agonist pilocarpine.

192 oncentrating hormone, TNRNFLRFamide, and the muscarinic agonist pilocarpine] in stomatogastric gangli

193 The non-selective muscarinic agonists pilocarpine, oxotremorine, RS-86, S-

194 phrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and proco

195 Optimal m1 muscarinic agonist potency was achieved when the 1,2,5-t

196 ed excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsy

197 Muscarinic agonists produced a concentration-dependent e

198 Pilocarpine (PILO), a muscarinic agonist, produces status epilepticus when adm

199 Muscarinic agonists promote recovery from dauer arrest i

200 Muscarinic agonists promoted microtubule depolymerizatio

201 muscarinic M1 receptors, bath application of muscarinic agonist reduced the maximal Po of Kv7.2/7.3 c

202 brain-wide functional substrates engaged by muscarinic agonists remain poorly understood.

203 Muscarinic agonists represent a new class of treatments

204 ntricular administration of centrally active muscarinic agonists resulted in robust analgesic effects

205 In phosphatidylinositol hydrolysis assays, muscarinic agonists showed greater potency at the HM(1)(

206 NHE1 is critical for regulating pHi during a muscarinic agonist-stimulated acid challenge and probabl

207 the rate of intracellular pH recovery from a muscarinic agonist-stimulated acid load was significantl

208 ator of intracellular pH in both resting and muscarinic agonist-stimulated acinar cells and suggest t

209 The spontaneous and muscarinic agonist-stimulated in vivo phasic contraction

210 y of ubiquitination of endogenous InsP3Rs in muscarinic agonist-stimulated SH-SY5Y human neuroblastom

211 By contrast, muscarinic agonist stimulation of the c-Jun NH2-terminal

212 and is principally under neural control with muscarinic agonists, substance P, and vasoactive intesti

213 In arteries, muscarinic agonists such as acetylcholine release an uni

214 6beta-Acyloxy(nor)tropanes and classical muscarinic agonists, such as muscarine and oxotremorine,

215 rebral hyperemic response to oxotremorine, a muscarinic agonist that increases cerebral blood flow (C

216 In the presence of a muscarinic agonist, the AHP of a subset of these interne

217 e volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signa

218 and that there is no requirement for potent muscarinic agonists to mimic acetylcholine interactions

219 fication, that although all areas respond to muscarinic agonists to some extent, only some areas are

220 Regulation of APP processing by the muscarinic agonist treatment occurred not only in normal

221 Muscarinic agonist treatment of hOPCs resulted in a spec

222 ermore, STIM2 siRNA prevented the effects of muscarinic agonist treatment on OPC differentiation sugg

223 ulfide cross-linking patterns indicated that muscarinic agonists trigger a separation of the N-termin

224 and compared it to a number of direct acting muscarinic agonists, two cholinesterase inhibitors and a

225 t the actions on KCNQ channels by Src and by muscarinic agonists use distinct mechanisms.

226 The M current is modulated by muscarinic agonists via G-proteins and an unidentified d

227 ound that, although the release of Ca2+ by a muscarinic agonist was reduced by high concentrations of

228 rd currents activated by 8-bromc-cGMP and by muscarinic agonist were compared in N1E-115 mouse neurob

229 In contrast, inverse muscarinic agonists were found to increase the proximity

230 Muscarinic agonists were tested in two models indicative

231 Muscarinic agonists, which produce an inward current in

232 ta-Acetoxynortropane (5) represents a potent muscarinic agonist with apparent selectivity toward M2-r

233 Other interneurons responded to muscarinic agonists with a hyperpolarization or a biphas

234 lso compared the RA(i) estimates of selected muscarinic agonists with a relative estimate of the prod

235 understand the nature of the interaction of muscarinic agonists with the m1 receptor using a nine am

236 viorally active dose of the M1/M4-preferring muscarinic agonist xanomeline on brain functional activi

237 idences of the antipsychotic activity of the muscarinic agonist xanomeline prompted us to investigate